No Data
Immutep Gains Positive Feedback From FDA on Phase 3 NSCLC Candidate Program
Immutep Announces Successful Meeting With FDA On Phase III Design In Non-Small Cell Lung Cancer; TACTI-004 Registrational Trial Will Enrol ~750 Patients Regardless Of PD-L1 Expression In Order To Address The Entire 1l NSCLC Market Eligible For...
Immutep Secures US FDA Guidance for Phase Three Lung Cancer Trial
Immutep Readies Phase III Lung Cancer Trial
Jefferies Remains a Buy on Immutep Ltd (PRRUF)
Immutep Receives Regulatory Clearance For Phase I Study Of First-In-Class LAG-3 Agonist Antibody Designed To Treat Autoimmune Diseases